Mirum Pharmaceuticals to Acquire Bluejay Therapeutics for Up to $820M

Why It Matters

The acquisition accelerates Mirum’s growth in the high‑need viral‑liver market, positioning it for broader commercial reach and diversified revenue streams. It also signals heightened consolidation activity among rare‑disease biotechs seeking scale and pipeline depth.

Key Takeaways

• Deal values Bluejay at up to $820M
• Mirum pays $250M cash, $370M stock
• Acquisition adds hepatitis B/Delta pipeline
• Potential $200M milestone payments tied to sales
• Mirum expands rare‑liver disease leadership

Pulse Analysis

The Mirum‑Bluejay transaction underscores a broader trend of consolidation in the rare‑disease sector, where mid‑stage biotechs are leveraging larger partners to accelerate development and market entry. By integrating Bluejay’s viral‑hepatitis assets, Mirum not only diversifies its therapeutic focus beyond cholestatic disorders but also gains access to a pipeline with clear regulatory pathways and unmet patient needs. This strategic fit is amplified by Mirum’s existing commercial infrastructure, which can expedite the rollout of Bluejay’s candidates once they achieve pivotal trial milestones.

Financially, the $820 million deal reflects a blended cash‑stock structure that balances immediate liquidity with long‑term equity participation, aligning incentives for both companies. The tiered milestone component, capped at $200 million, ties future payouts to commercial performance, mitigating upfront risk while rewarding successful market penetration. For investors, the acquisition broadens Mirum’s revenue base, potentially smoothing earnings volatility inherent to rare‑disease portfolios that often rely on single‑product sales.

From a clinical perspective, Bluejay’s focus on chronic hepatitis B and Delta addresses a global health burden affecting over 300 million people. The combination regimen featuring cavrotolimod and BJT‑628 aims for a functional cure, a milestone that could reshape treatment standards and command premium pricing. Mirum’s expertise in liver‑targeted therapies, exemplified by its approved LIVMARLI® and CHOLBAM® products, provides a synergistic platform to advance these programs through late‑stage trials and eventual commercialization, reinforcing its position as a leader in rare‑liver disease therapeutics.

Deal Summary

Mirum Pharmaceuticals announced it will acquire biotech firm Bluejay Therapeutics in a deal valued at up to $820 million, comprising cash, stock, and potential milestone payments. The transaction, approved by both boards, is slated to close in Q1 2026 pending regulatory approval.